Abstract: Use of Idazoxan or an active enantiomer thereof, and treatment of patients receiving therapy with selective serotonin uptake inhibitor(s), such as Fluoxetine, Citalopram, Paroxetine, Sertraline and Fluvoxamine, are described. The patients being treated are in particular those who are suffering from severe depression, anxiety-depression, PTSD (Post Traumatic Stress Disorder), or ADHD (Attention Deficit Hyperactive Disorder).

Abstract: The present invention provides novel antipsychotic therapies and compositions useful therein and provides methods for identifying new candidate molecules for the treatment of psychosis based on the proportional binding affinities for ?2 adrenergic and D2 dopamine receptors.

Abstract: A composition comprising: (a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof is provided. The composition is useful in treating disorders or diseases of the central nervous system, and particularly useful in treating schizophrenia.

Abstract: A composition comprising: (a) a pharmaceutically effective amount of reboxetine; and selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof is provided.

Abstract: The present invention provides novel antipsychotic therapies and compositions useful therein and provides methods for identifying new candidate molecules for the treatment of psychosis based on the proportional binding affinities for &agr;2 adrenergic and D2 dopamine receptors.

Abstract: A method of producing a 6-substituted (S)-nicotine derivative with the general formula (III), wherein R is an optionally substituted alkyl, alkenyl, alkynyl, amido or amino group, optionally coupled to a carrier protein, is disclosed. An intermediate compound useful in the method is also comprised by the invention. The formula of the compound is (A) in which A represents the cationic radical of an organic nitrogen base, Y represents an anion formed by an electrophilic compound.

Abstract: A 5- or 6-nicotinyl-linker-carrier protein compound and immunogen having formula (a) wherein X is —NH—CO— or NH— or —C≡C— or —C═C— or CH2—; Y is —(CH2)k— or —(CH2)m—C6H10—(CH2)n— or (CH2)m—C6H4—(CH2)n— when Z is —NH—, with the proviso that X is not —NH—CO— when Y is (CH2)5 and Z is —NH—, and X is —NH—CO— or —C≡C— or —C═C— or CH2—, Y is —(CH2)m—C6H10—(CH2)n— or —(CH2)m—C6H4—(CH2)n—, when Z is —CO—, and X is —C≡C— or —C═C—, Z is —CO—, when Y is (CH2)k—, is disclosed. The compound may be used as a medicament, suitably in the form of a pharmaceutical composition.

Abstract: A method of producing a 6-substituted (S)-nicotine derivative with the general formula (III), wherein R is an optionally substituted alkyl, alkenyl, alkynyl, amido or amino group, optionally coupled to a carrier protein, is disclosed. An intermediate compound useful in the method is also comprised by the invention. The formula of the compound is (A) in which A represents the cationic radical of an organic nitrogen base, Y represents an anion formed by an electrophilic compound.

Abstract: A composition comprising: